The t(14;18)(q32;q21) translocation is closely associated with follicular lymphoma (FL), and is routinely assessed with molecular methods exploring BCL2 breakpoints for both diagnosis and minimal residual disease (MRD) monitoring. We and others have previously reported new recurrent breakpoints (3ЈBCL2 and 5Јmcr) which could be easily analyzed. In this study, we characterized the BCL2 breakpoints in 113 untreated patients with t(14;18)-positive FL and correlated their location with the location of JH break and with the clinical features. Breakpoints were respectively located at the major breakpoint region (MBR) in 73 cases (65%), at the minor cluster region (mcr) in 10 cases (9%), at 3ЈBCL2 in 14 cases (12%) and at 5Јmcr in seven cases (6%). Finally, the breakpoint could not be located in nine patients (8%). 5Јmcr cases were associated with bulky and high-stage disease, with frequent extranodal involvement and bone marrow infiltration. Survival studies did not show any correlation between breakpoint location and clinical outcome. The joining JH6 segment was the most frequently involved whatever the breakpoint location. In conclusion, unusual BCL2 breakpoints are found in about 20% of newly diagnosed follicular lymphomas and their study should be considered in the investigation of BCL2-JH rearrangement. It was not possible, in this series, to demonstrate any correlation between breakpoint location and either initial characteristics of the disease or survival of the patients.
Background: Immunotherapy using chimeric antigen receptor (CAR) T cells has demonstrated profound, durable success in hematologic malignancies. Solid tumors present hurdles to the successful application of CAR T cells. One is the upregulation of inhibitory receptors (IRs), like PD1 and CTLA4, many of which rely on shared signaling molecules to shut off T cell activation. One such molecule is SHP1 (Src homology region 2 domain-containing phosphatase-1) which dephosphorylates key components of T cell receptor (TCR) signaling. We have engineered a unique dominant-negative SHP1 (dnSHP1) that is able to augment CAR T cell control of PDL1 positive solid tumors. Materials and Methods: The human mesothelioma cell line, EMP, was transduced to express high levels of mesothelin and PDL1 (EMMESO-PDL1). Activated human T cells from healthy donors were lentivirally transduced to express a mesothelin-directed CAR (mesoCAR) with and without a dnSHP1. MesoCAR and mesoCAR/dnSHP1 T cells were cocultured with tumor cells x 18hrs and specific lysis was measured. These T cells were also restimulated with plate-bound anti-CD3 overnight and were subjected to intracellular flow cytometry staining (ICS) of cytokines. NSG mice were injected subcutaneously in the flanks with 5x106 EMMESO-PDL1 tumor cells. After tumors established and grew to ~150mm3, mice were randomly assigned to one of the following treatments: 1) non-transduced (NTD) T cells, 2) mesoCAR T cells, 3) mesoCAR T cells + sodium stibogluconate (SSG; a chemical inhibitor of SHP1), 4) mesoCAR/dnSHP1 T cells. T cells were injected IV once at a dose of 10x106 T cells/mouse. SSG was administered IM at 20mg/kg every 2 days. Tumors were measured serially. At the end, mice were sacrificed, tumors were harvested, digested, processed into single cell suspension, and subjected to flow cytometry analysis. The tumor infiltrating lymphocytes (TILs) were also isolated and tested for function ex-vivo. Results/Conclusion: In vitro, mesoCAR T cells demonstrated suppressed lysis of EMMESO-PDL1 tumor cells compared to EMMESO cells. MesoCAR/dnSHP1 T cells were able to lyse EMMESO-PDL1 and EMMESO tumor cells with similar efficiency. Anti-CD3 restimulation of T cells revealed enhanced secretion of TNF-alpha and IL2 by mesoCAR/dnSHP1 vs. mesoCAR T cells as measured by ICS. In vivo, SSG injections had minimal impact on mesoCAR T cell control of tumors, whereas mesoCAR/dnSHP1 T cells demonstrated significantly enhanced control of EMMESO-PDL1 tumor growth compared to mesoCAR T cells (60% greater decrease in tumor volume compared to mesoCAR T cells). TIL infiltration was 3-fold higher in tumors harvested from mice that received mesoCAR/dnSHP1 T cells compared to other groups. Isolated mesoCAR/dnSHP1 TILs demonstrated the greatest ex-vivo lysis of fresh tumor cells. DnSHP1 engineering is a powerful and novel way of blocking the suppression of CAR T cells by PD1 and other similar IRs. Citation Format: Edmund Moon, Soyeon Kim, Naomi Saint Jean, Shaun O'Brien, Steven Maceyko, Jing Sun, Carl June, Steven Albelda. Genetic blockade of the protein tyrosine phosphatase SHP1 augments CAR T cell activity against PDL1 expressing solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3749. doi:10.1158/1538-7445.AM2017-3749
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.